Taxanes in ovarian cancer treatment.
Paclitaxel and docetaxel are active in the treatment of patients with advanced ovarian cancer. The taxanes in various dose schedules achieve response rates of 10-50% with a median overall survival of 10-12 months in patients with platinum-refractory disease. Paclitaxel has activity in chemotherapy-naive patients when administered alone or in combination with platinum. The role of intraperitoneal paclitaxel remains to be defined.
Seetalarom
K
K
Pramongkutklao College of Medicine, Bangkok, Thailand.
Kudelka
A P
AP
Verschraegen
C F
CF
Kavanagh
J J
JJ
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015996:Survival Rate; D043823:Taxoids; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel